The MD Magazine Arthritis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.


FDA Approves Infliximab Biosimilar
Infliximab-abda approved for range of gastroenterological and rheumatoid conditions.
At one year, nearly as many on monotherapy were in remission as on combo therapy.
Company hopes former RA candidate will be approved for rare blood condition.
Prolonged, repetitive hard work is a risk factor for RA, according to a new study.
Sarilumab patients had less disease activity and pain, greater response rates.
FDA rejects potential blockbuster, requesting further safety data.
Companies race to join tofacitinib on the rheumatoid arthritis treatment market.
Alone or combined with methotrexate, benefits continued through week 104.
16.8% of RA patients in the study presented with major depression.

Most Popular


$vacMongoViewPlus$ $vAR$